Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,508 | 0 | N/A | 0 | 0 |
| TOTAL | $21,354 | $0 | $N/A | $0 | $0 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 144 | 0 | 0 | 0 | 0 |
| TOTAL | $144 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $21,498 | $0 | $N/A | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,723 | 0 | 0 | 0 | 0 |
| Accrued Expenses | 2,424 | 0 | N/A | 0 | 0 |
| TOTAL | $5,287 | $0 | $N/A | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 214,625 | 0 | 0 | 0 | 0 |
| TOTAL | $214,625 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $219,912 | $0 | $N/A | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 21,355 | N/A | N/A | N/A | N/A |
| Common Shares | 1 | 0 | N/A | 0 | 0 |
| Retained earnings | -235,240 | 0 | N/A | 0 | 0 |
| TOTAL | $-198,414 | $0 | $N/A | $0 | $0 |
| Total Liabilities And Equity | $21,498 | $0 | $0 | $0 | $0 |